A PYMNTS Company

Swiss Competition Watchdog Probes Novartis

By  |  September 21, 2022

The Swiss competition commission (COMCO) has opened an investigation of Novartis over possible unlawful use of a patent to reduce competitive pressure, the Swiss drugmaker confirmed on Thursday.

    Get the Full Story

    Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.

    yesSubscribe to our daily newsletter, PYMNTS Today.

    By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions.

    COMCO conducted an early morning raid on the company on September 13th, it said in a statement that did not name Novartis, which subsequently said in its own statement that it was the group under investigation.

    “The company allegedly attempted to protect its drug for the treatment of skin diseases against competing products by using one of its patents to initiate litigation proceedings,” COMCO said in a statement.

    Novartis said COMCO had started an investigation in collaboration with the European Commission into the assertion of a patent in the broader field of dermatology treatments.

    “In connection with this investigation, COMCO representatives visited the company headquarters in Basel,” it said.

    “The opening of an investigation does not imply any finding of wrongdoing or any financial impact. Novartis is fully cooperating with the authorities and is confident to clarify the legitimacy of its position,” it added.

    Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.